HealthPartially Done
Facilitate global Yoga and Ayurveda institutes and a certification mechanism
Bharatiya Janata PartyhighOct 20260
On Trackhigh confidenceHealth
Strengthen Bharat as the Pharmacy of the World, boost APIs and research
Bharatiya Janata Party · Lok Sabha General Election 2024
Last updated 25 Oct 2026
What does this status mean?
Implementation is progressing towards the commitment.
Status describes delivery. Confidence describes how strong the available evidence is.
Original manifesto wording
“We will strengthen Bharat's position as the 'Pharmacy of the World' by boosting the manufacturing and research capacities of the pharmaceutical sector, especially APIs. We will expand Research Linked Incentive schemes, encouraging companies to invest in research for new drugs, chemical entities and new biological entities.”
From the Bharatiya Janata Party manifestoView Manifestop.43
Our Assessment
Pharmaceutical exports rose from US$27.85 billion in FY2023–24 to about US$31 billion in FY2025–26. By June 2026, 39 bulk-drug PLI projects had been commissioned; PRIP research centres had begun work, and 41 industry innovation projects were approved in September. But some commissioned API capacity was not in commercial production, imports remained concentrated, and new-drug outcomes are not yet verified. The broad promise is On Track.
The reasoning behind the verdict
Why this assessment?
Reviewed
01 · Delivery status
Why on track?
This is an open-ended commitment to expand pharmaceutical manufacturing and research. Post-election export growth, commissioned API projects, actual PLI investment and sales, funded PRIP research centres, and 41 approved innovation projects show substantive continuing implementation. It is not Fulfilled: commissioned capacity does not always mean commercial production, substantial API import dependence remains, and approval of research projects does not establish delivery of new drugs or biological entities.
02 · Strength of evidence
Why high confidence?
High confidence is based on Ministry of Commerce export figures and Department of Pharmaceuticals releases and parliamentary replies reporting investments, project commissioning, actual API production, research-centre funding and PRIP approvals. These sources also disclose the important gaps, which are reflected in the verdict.
What would help us reassess?
The documents that could clarify delivery of this commitment.
- Product-wise commercial output from bulk-drug PLI plants, including the 10 API/KSM/DI products lacking commercial production as of March 2026
- Comparable post-2024 API import volumes and China share to test actual import substitution
- PRIP disbursements and research milestones for the 41 approved industry projects
- Regulatory approvals or commercial launches of new chemical and biological entities supported by PRIP
Status describes delivery. Confidence describes the evidence.
Read our methodology ↗Sources & Evidence
government
Department of Pharmaceuticals - PLI for bulk drugs/APIs and bulk drug parks (DoP)
pharmaceuticals.gov.in·1 Jan 2025
government
Department of Pharmaceuticals expenditure budget 2026-27
indiabudget.gov.in·1 Feb 2026
government
PRIP scheme and pharma sector innovation support
pib.gov.in·22 Jul 2025
government
PRIP Scheme aims to transform Indian PharmaMedTech sector through innovation
pib.gov.in·9 Dec 2025
government
Department of Pharmaceuticals 2025 review: PLI production and PRIP research outputs
pib.gov.in·6 Jan 2026
government
Parliamentary reply on imported APIs and source countries
pib.gov.in·3 Feb 2026
government
Bulk Drug Park Scheme approved parks and outlay
pib.gov.in·6 Feb 2026
government
Parliamentary reply on PRIP Centres of Excellence and funds released
pib.gov.in·10 Feb 2026
government
Extension and progress of PLI Scheme for APIs
pib.gov.in·13 Mar 2026
government
Ministry of Commerce statement on FY2025-26 pharmaceutical exports
pib.gov.in·9 Jun 2026
government
12 years of transformative growth in pharmaceuticals
pib.gov.in·17 Jun 2026
government
Parliamentary reply on bulk-drug PLI production, investment and incentive disbursement
pib.gov.in·7 Aug 2026
government
Department of Pharmaceuticals update on PLI manufacturing and sales
pib.gov.in·25 Sept 2026
government
PRIP first-round approvals for 41 pharma and medtech innovation projects
pib.gov.in·30 Sept 2026
government
FY2024-25 drugs and pharmaceuticals export figures
pib.gov.in·16 Apr 2025
Promise Timeline
30 Sept 2026
The first PRIP industry round approved 41 innovation projects for about ₹1,600 crore of assistance, including 27 New Medicines projects. These are approvals, not completed new drugs or confirmed disbursements.
View source25 Sept 2026
Department of Pharmaceuticals reported that, as of June 2026, 39 bulk-drug PLI projects for 28 APIs/KSMs had been commissioned, with ₹5,210.74 crore invested and ₹3,792.49 crore in sales. The broader pharmaceuticals PLI had ₹46,744 crore of actual investment.
View source7 Aug 2026
A parliamentary reply said capacity existed for 28 bulk-drug PLI products as of March 2026, but 10 had not reached commercial production; production had begun for 18. Cumulative investment was ₹5,070.45 crore.
View source17 Jun 2026
PIB reported that the PLI Scheme for Pharmaceuticals had attracted cumulative investments of Rs 42,694.89 crore and cumulative sales of Rs 3,43,215.27 crore.
View source9 Jun 2026
The Commerce Ministry reported pharmaceutical exports of about US$31 billion in FY2025–26, with Indian medicines reaching more than 200 countries.
View source13 Mar 2026
Government reported that 38 projects covering 28 notified products had been commissioned under the PLI Scheme for Bulk Drugs, creating about 56,800 MT per annum domestic manufacturing capacity.
View source10 Feb 2026
A parliamentary reply confirmed seven PRIP Centres of Excellence at NIPERs and ₹183.46 crore released for setting them up through 31 January 2026.
View source6 Feb 2026
Department of Pharmaceuticals reported that three Bulk Drug Parks were approved in Gujarat, Himachal Pradesh and Andhra Pradesh, with Rs 3,000 crore scheme outlay and grant-in-aid of Rs 1,000 crore for each park.
View source3 Feb 2026
A parliamentary reply reported US$4.35 billion of API, bulk-drug and drug-intermediate imports in FY2024–25; 73.7% came from China, showing continuing import dependence.
View source6 Jan 2026
Department of Pharmaceuticals reported that, by November 2025, seven PRIP Centres of Excellence had approved 111 research projects, published 46 papers and filed six patents.
View source22 Jul 2025
Department of Pharmaceuticals reported the PRIP scheme with Rs 5,000 crore outlay and seven NIPER Centres of Excellence with total budgetary support of Rs 700 crore.
View source16 Apr 2025
Ministry of Commerce reported drugs and pharmaceuticals exports of US$30.47 billion in FY2024–25, up 9.39% from US$27.85 billion in FY2023–24.
View sourceRelated Promises
Have evidence on this promise?
Help us track this promise by submitting news articles, government orders, or any other evidence you've found.
Submit Evidence